Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Mission Bio Blog and Podcast go live! Get the latest news and trends on single-cell multi-omics. Subscribe
X
Scientific presentation

Investigation of AML clonal architecture with mutational and immunophenotypic profiling simultaneously from the same cell(s)


Linde Miles, PhD
Description

Acute myeloid leukemia (AML) is a molecularly diverse hematology disease with a poor survival rate. Only 25% of patients diagnosed survive. Therefore, it is important to gain a better understanding of the disease progression by using new technologies like single-cell DNA sequencing. Leukemogenesis is thought to be a stepwise process. However, bulk sequencing only infers the order of mutation acquisition. Linde Miles, of Ross Levine’s lab at Memorial Sloan Kettering Cancer Center, shares findings from her study where she immunophenotyped and genotyped AML samples to track the order of mutations using a custom molecular panel, covering key genes for AML, MPN, and MDS. Furthermore, through a simple add-on to the workflow, she confirmed protein expression with molecular data to understand enrichment and differentiation patterns. Discover how the Tapestri Platform provides a true multi-omics approach for deeper insight into systems biology and patterns of tumor evolution, therapy response, and resistance.



VIEW


Scientific presentation
Women in Single Cell: Elucidating Clonal Evolution and Clonotype-Immunophenotype Relationships in Myeloid Malignancies with Single-Cell Analysis
Linde Miles, PhD, Memorial Sloan Kettering Cancer Center
(2021)
Scientific presentation
Meet the Authors: Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies
Ross Levine, MD, Memorial Sloan Kettering Cancer Center
(2021)
Scientific presentation
Utilizing Single-Cell Multi-Omics to Uncover its Evolution and Resistance Mechanisms of AML
Cathy Smith, MD, UCSF
(2021)
Scientific presentation
A New Single-Cell Sequencing and Analysis Platform to Accelerate Cell and Gene Therapy Pipelines
Matt Cato & Shu Wang, Mission Bio
(2021)